No Data
No Data
Insider Sale: SVP & CFO of $BVS (BVS) Sells 10,733 Shares
JP Morgan Upgrades Bioventus to Neutral, Raises Price Target to $13
Bioventus: Strategic Moves Amidst Financial Challenges Justify Hold Rating
J.P. Morgan Upgrades Bioventus(BVS.US) to Hold Rating, Raises Target Price to $13
Express News | Bioventus Inc : JP Morgan Raises to Neutral From Underweight; Raises Target Price to $13 From $12
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
No Data